D&A at other companies
Other financials
Where this comes from
Reported directly by Enliven Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:Depreciation.
The official record: Enliven Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Enliven Therapeutics's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Enliven Therapeutics's D&A?
- Enliven Therapeutics (ELVN) reported D&A of $14K in Q1 2026.
- How has Enliven Therapeutics's D&A changed year-over-year?
- Enliven Therapeutics's D&A decreased by 81.1% year-over-year, from $74K to $14K.
- What is the long-term trend for Enliven Therapeutics's D&A?
- Over 4 years (2021 to 2025), Enliven Therapeutics's D&A has grown at a 27.7% compound annual growth rate (CAGR), from $99K to $263K.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.